Clinical Trial Update: Pazopanib and Paclitaxel as First-Line Treatment for Subjects With Unresectable Stage III and Stage IV Melanoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating pazopanib in combination with paclitaxel as first-line therapy for unresectable Stage III and Stage IV melanoma; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• PACLITAXEL (PACLITAXEL)
• Pazopanib (Pazopanib)

Snippet

Sponsor: University of California, Irvine | Conditions: Stage III Melanoma, Stage IV Melanoma | Phase 2 | Status: COMPLETED | Results posted: 2019-02-01